Biotech Stock Mailbag: HEB's Artful Dodging
Lately, there's been plenty to write about with regard to Cell Therapeutics, but a quick check of our Web site will demonstrate that the stock is far from the only thing coming off my keyboard these days.
The answer to Golden's question is no, I don't hate Cell Therapeutics, nor do I have any personal vendetta against it or CEO Jim Bianco. I don't make this job personal. I like to find good stories to write about -- stories that hopefully help investors make some money in biotech. (The best way to do that, sometimes, is to avoid buying certain stocks.) If the stories are controversial, it's all the better, because those are usually the most fun.
Clearly I think Cell Therapeutics is an over-valued stock relative to its commercial prospects for the cancer drugs pixantrone and Opaxio. The company's capital structure and finances are a mess. This is what my recent "drum-beating" on Cell Therapeutics is all about.
And to answer the most obvious follow-up question: No, I have no financial interest in Cell Therapeutics. I've never owned the stock, nor have I ever shorted the stock. You can read TheStreet.com's conflict of interest policy here. I'll even go one step further and tell you that during my two-year stint as a Wall Street analyst, my employer never had a position in Cell Therapeutics, either.
John C. writes, "As a practicing physician and an investor, I have been anxiously awaiting the FDA's decision for Cardiome's (CRME) atrial fibrillation medication. Is it unusual for them to take so long? This is potentially a very useful drug and all that I have read about it makes me think it is safe and effective. I don't understand the FDA's seeming reluctance to give it approval."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV